申请人:IMPERIAL CHEMICAL INDUSTRIES PLC
公开号:EP0316097A1
公开(公告)日:1989-05-17
Naphtho[2,1-b]furan derivatives of the formula:-
wherein
R¹ is a 1H-1,2,4-triazol-1-yl, 4H-1,2,4-triazol-4-yl, 3-pyridyl or 5-pyrimidinyl radical or a 1H-imidazol-1-yl radical optionally substituted in the 5-position by a 1-6C alkyl or halogenoalkyl radical;
R² and R³, which may be the same or different, are each a hydrogen or deuterium atom, a cyano radical, a 1-6C alkyl or halogenoalkyl radical, a phenyl radical optionally substituted by halogen, or one of R² and R³ is a radical of the formula R¹ as defined above, and the other is hydrogen;
R⁴ and R⁵, which may be the same or different, are each a 1-2C alkyl, deuterioalkyl or halogenoalkyl radical;
or R⁴ and R⁵ together with the carbon atom to which they are attached form a 3-6C cycloalkyl radical;
R⁶ and R⁷, which may be the same or different, are each a hydrogen or halogen atom, an amino, carboxy, carbamoyl, cyano, 1-cyano-1-methylethyl or nitro radical, a 1-6C alkyl or halogenoalkyl radical, a mono- or di-(1-6C)alkylcarbamoyl radical, a mono- or di-(1-6C)halogenoalkylcarbamoyl radical, a group of the formula -COR⁸, -SOnR⁸ or -OR⁸, in which n is 0, 1 or 2 and R⁸ is a 1-6C alkyl or halogenoalkyl radical, or a benzoyl radical optionally substituted by halogen;
one of R⁹ and R¹⁰ is hydrogen and the other is a hydroxy or 1-6C alkoxy radical, or R⁹ and R¹⁰ together form an oxo radical; and the pharmaceutically acceptable acid addition salts thereof;
processes for their manufacture; and pharmaceutical compositions containing them.
式中的
萘并[2,1-b]
呋喃衍
生物
其中
R¹ 是
1H-1,2,4-三唑-1-基、4H-
1,2,4-三唑-4-基、3-
吡啶基或 5-
嘧啶基,或在 5 位上任选被 1-6C 烷基或卤代烷基取代的
1H-咪唑-1-基;
R²和R³可以相同或不同,各自为氢原子或
氘原子、
氰基、1-6C烷基或卤代烷基、任选被卤素取代的苯基,或者R²和R³中的一个为上式R¹定义的基,另一个为氢;
R⁴ 和 R⁵ 可以相同或不同,各自为 1-2C 烷基、
氘代烷基或卤代烷基;
或 R⁴ 和 R⁵ 与它们所连接的碳原子一起形成 3-6C 环烷基;
R⁶ 和 R⁷ 可以相同或不同,各自为氢原子或卤素原子、
氨基、羧基、
氨基甲酰基、
氰基、1-
氰基-1-甲基乙基或硝基、1-6C 烷基或卤代烷基、单-或二-(1-6C)烷基
氨基甲酰基、单-或二-(1-6C)卤代烷基
氨基甲酰基,式-COR⁸、-SOnR⁸或-OR⁸的基团,其中 n 为 0、1 或 2,R⁸ 为 1-6C 烷基或卤代烷基,或任选被卤素取代的苯甲酰基;
R⁹和 R¹⁰ 中的一个是氢,另一个是羟基或 1-6C 烷氧基,或 R⁹ 和 R¹⁰ 共同形成一个氧代基;及其药学上可接受的酸加成盐;
它们的制造工艺;以及含有它们的药物组合物。